Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis.

Autor: Thaçi, Diamant1 (AUTHOR) diamant.thaci@uksh.de, Singh, Dave2 (AUTHOR), Lee, Mark3 (AUTHOR), Timmis, Helen4 (AUTHOR), Jacobs, Dominique4 (AUTHOR), Passier, Paul4 (AUTHOR), Rohrer, Susanne5 (AUTHOR), Beetens, Johan4 (AUTHOR), Phung, De4 (AUTHOR), Sondag, Eric4 (AUTHOR), Babic, Goran6 (AUTHOR), Würth, Guido6 (AUTHOR), Kloepfer, Pia6 (AUTHOR), Härtle, Stefan6 (AUTHOR), Hüttner, Silke4 (AUTHOR)
Zdroj: Journal of Clinical Medicine. Dec2022, Vol. 11 Issue 23, p7244. 16p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje